Core Insights - NeoGenomics, Inc. will present new data on comprehensive genomic profiling (CGP) for myeloid malignancies at the 67th American Society of Hematology Annual Meeting in December 2025 [1] - The study highlights the effectiveness of the Neo Comprehensive Myeloid panel, a next-generation sequencing assay that aids in diagnosing and guiding treatment for myeloid cancers [2][3] Company Overview - NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, providing a comprehensive oncology-focused testing menu [5] - The company operates CAP-accredited and CLIA-certified laboratories across the US and in the UK, ensuring high-quality sample processing and analysis [5] Research Findings - The analysis involved 533 patients with myeloid disorders, revealing that CGP identified pathogenic changes earlier in about one-third of the cases, leading to diagnostic reclassification [3] - The study uncovered rare but clinically significant fusions, such as PDGFRA, PDGFRB, FGFR1, and JAK2, which informed targeted treatment decisions [3] Leadership Statement - The President and COO of NeoGenomics emphasized the company's commitment to improving cancer care by providing advanced diagnostic tools that enable personalized treatment decisions for patients with complex blood cancers [4]